[HTML][HTML] DNA repair targeted therapy: The past or future of cancer treatment?

NS Gavande, PS VanderVere-Carozza… - Pharmacology & …, 2016 - Elsevier
The repair of DNA damage is a complex process that relies on particular pathways to
remedy specific types of damage to DNA. The range of insults to DNA includes small …

Parthanatos: mitochondrial‐linked mechanisms and therapeutic opportunities

AA Fatokun, VL Dawson… - British journal of …, 2014 - Wiley Online Library
Cells die by a variety of mechanisms. Terminally differentiated cells such as neurones die in
a variety of disorders, in part, via parthanatos, a process dependent on the activity of poly …

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a …

S Loibl, J O'Shaughnessy, M Untch, WM Sikov… - The lancet …, 2018 - thelancet.com
Background Although several randomised trials in patients with triple-negative breast cancer
have shown that the addition of carboplatin, with or without poly (ADP-ribose) polymerase …

[HTML][HTML] PARPs in lipid metabolism and related diseases

M Szántó, R Gupte, WL Kraus, P Pacher… - Progress in Lipid Research, 2021 - Elsevier
PARPs and tankyrases (TNKS) represent a family of 17 proteins. PARPs and tankyrases
were originally identified as DNA repair factors, nevertheless, recent advances have shed …

TXNIP: A Double‐Edged Sword in Disease and Therapeutic Outlook

M Pan, F Zhang, K Qu, C Liu… - Oxidative Medicine and …, 2022 - Wiley Online Library
Thioredoxin‐interacting protein (TXNIP) was originally named vitamin D3 upregulated
protein‐1 (VDUP1) because of its ability to bind to thioredoxin (TRX) and inhibit TRX …

XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia

NC Hoch, H Hanzlikova, SL Rulten, M Tétreault… - Nature, 2017 - nature.com
XRCC1 is a molecular scaffold protein that assembles multi-protein complexes involved in
DNA single-strand break repair,. Here we show that biallelic mutations in the human XRCC1 …

Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors

P Jagtap, C Szabó - Nature reviews Drug discovery, 2005 - nature.com
Abstract Poly (ADP-ribose) polymerases (PARPs) are involved in the regulation of many
cellular functions. Three consequences of the activation of PARP1, which is the main isoform …

Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases

NA Berger, VC Besson, AH Boulares… - British journal of …, 2018 - Wiley Online Library
The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for
potential therapeutic repurposing for non‐oncological indications. Considering (a) the …

Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration

A Wenzel, C Grimm, M Samardzija, CE Remé - Progress in retinal and eye …, 2005 - Elsevier
Human retinal dystrophies and degenerations and light-induced retinal degenerations in
animal models are sharing an important feature: visual cell death by apoptosis. Studying …

The mitochondrial permeability transition from in vitro artifact to disease target

P Bernardi, A Krauskopf, E Basso, V Petronilli… - The FEBS …, 2006 - Wiley Online Library
The mitochondrial permeability transition pore is a high conductance channel whose
opening leads to an increase of mitochondrial inner membrane permeability to solutes with …